For example, using a specific gene signature for KRAS dependency, recently led to the identification and validation of decitabine as a potent inhibitor of growth in KRAS-dependent pancreatic cancer cells and patient-derived xenograft models [29], an approach that is now being translated to the clinic. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.